Clinical Trial Update: Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating venetoclax with azacitidine and CAG regimen in refractory/relapsed acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CAG regimen
• Venetoclax (venetoclax)

Snippet

Sponsor: Hematology department of the 920th hospital | Conditions: Refractory/Relapse Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN